Rate of Cesarean Section
| Group | Value (participants) |
|---|---|
| Vaginal Misoprostol | 27 |
| Oxytocin Alone | 26 |
Trial · Interventional
CompletedNot applicableResults postedRegistry dataUnited States
1 trial · 1 completed · 1 with posted results
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Premature rupture of membranes (PROM) is diagnosed by demonstrating amniotic fluid in the vaginal canal before the onset of labor. The integrity of the amniotic membrane is compromised thereby increasing the risk of intrauterine infection and compression of the umbilical cord. PROM complicates 3% to 8% of pregnancies in the US and is responsible for 30% of preterm births. Intrauterine infection remains the most significant maternal and neonatal sequelae associated with PROM and this risk increases with the length of time from ruptured membrane to delivery. Induction of labor has been shown to reduce the rates of chorioamnionitis, endometritis and NICU admissions4. Specifically, induction of labor with prostaglandin agents followed by oxytocin, versus oxytocin alone has been shown to be effective for labor induction resulting in vaginal delivery. Management strategies for PROM have been controversial, and published studies on outcomes are over one to two decades old, which does not account for changes in clinical trends and practice patterns. Recently ACOG recommends that patients presenting at 37 weeks gestation or greater with PROM should be induced if not in labor, and "generally with oxytocin". In women with PROM without the onset of labor, the cervix is commonly unfavorable and induction with oxytocin alone may lead to an increased risk of cesarean section. With a c-section rate as high as 33%, women undergoing induction of labor have an increased risk of c-section and its associated morbidity and long term sequela. ACOG's recommendation for the use of oxytocin as the induction agent may be meant to avoid a theoretical increased risk of chorioamnionitis in this patient population however it does not take into account the status of the cervix, which may result in a increased risk of c-section. The purpose of the proposed study is to determine whether cervical ripening in women with PROM and an unfavorable cervix is associated with increase rates of vaginal delivery and decreased cesarean section rate compared to induction of labor with oxytocin alone. The investigators aim to determine the incidence of endometritis, and neonatal infection associated with PROM in the current medical environment of antibiotic prophylaxis and antenatal steroid use, taking into account the changes in patient characteristics.
Active comparator
Misoprostol
Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
Active comparator
Oxytocin Alone
Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
Outcomes the sponsor listed as primary.
Rate of Cesarean Section
Time frame · within 48 hours
Mode of delivery via cesarean section or vaginal delivery
Maternal and Neonatal Infectious Morbidity
Time frame · within 72 hours
Maternal infection defined as fever \>100.4 on at least two occasions during labor, continued antibiotic treatment on or after PPD#1, histologic confirmation of chorioamnionitis. Dose of Oxytocin, Tachysystole, Estimated blood loss at delivery, maternal length of stay, Epidural use, Indication for cesarean delivery Neonatal infection defined as WBC \<5000 and absolute neutrophil count \<1000 or positive blood cultures and neonatal fever, NICU admission, Apgar score less than 7 at 5 minutes,
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (participants) |
|---|---|
| Vaginal Misoprostol | 27 |
| Oxytocin Alone | 26 |
| Group | Value (Participants) |
|---|---|
| Vaginal Misoprostol | 13 |
| Oxytocin Alone | 15 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| MisoprostolThose randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol. Misoprostol: Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider. | 0 / 117 | 0 / 117 | 0 / 117 |
| Oxytocin AloneThose randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions. Oxytocin: Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions. | 0 / 113 | 0 / 113 | 0 / 113 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
8 studies on this page
Indexing hint: Randomized controlled trial · 2011
Balci et al. 2011The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricianscited by 5
PMID 21087166DOI 10.3109/14767058.2010.531798PUB-21087166
Indexing hint: Meta-analysis (pooled) · 2006
Dare et al. 2006The Cochrane database of systematic reviewscited by 48
PMID 16437525DOI 10.1002/14651858.cd005302.pub2PUB-16437525
Indexing hint: Randomized controlled trial · 1999
Merrill et al. 1999Obstetrics and gynecologycited by 59
PMID 10472877DOI 10.1016/s0029-7844(99)00338-5PUB-10472877
Indexing hint: Randomized controlled trial · 1998
Wing et al. 1998American journal of obstetrics and gynecologycited by 44
PMID 9704771DOI 10.1016/s0002-9378(98)70256-xPUB-09704771
Indexing hint: Randomized controlled trial · 1996
Hannah et al. 1996The New England journal of medicinecited by 256
PMID 8598837DOI 10.1056/nejm199604183341601PUB-08598837
Indexing hint: Randomized controlled trial · 1994
Gonen et al. 1994American journal of perinatologycited by 9
PMID 7857439DOI 10.1055/s-2007-994615PUB-07857439
Indexing hint: Randomized controlled trial · 1992
Mahmood et al. 1992British journal of obstetrics and gynaecologycited by 21
PMID 1554660DOI 10.1111/j.1471-0528.1992.tb14466.xPUB-01554660
Indexing hint: Randomized controlled trial · 1984
Duff et al. 1984Obstetrics and gynecologycited by 72
PMID 6717874PUB-06717874
References listed at the registry that are not in PepBank. They link to PubMed.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated